Literature DB >> 18091551

Effects of the TREM-1 pathway modulation during mesenteric ischemia-reperfusion in rats.

Sébastien Gibot1, Frédéric Massin, Corentine Alauzet, Chantal Montemont, Alain Lozniewski, Pierre-Edouard Bollaert, Bruno Levy.   

Abstract

OBJECTIVES: The triggering receptor expressed on myeloid cells (TREM)-1, a receptor expressed on the surface of neutrophils and monocytes/macrophages, synergizes with the Toll-like receptors in amplifying the inflammatory response mediated by microbial components. Because the pathogenesis of ischemia-reperfusion-induced gastrointestinal tissue injury and multiple organ failure implies leukocyte activation and bacterial translocation, we hypothesized that the TREM-1 pathway modulation would prove beneficial in this setting.
DESIGN: Animal study.
SETTING: Research laboratory.
SUBJECTS: Adult male Wistar rats (250-300 g).
INTERVENTIONS: Rats were subjected to intestinal ischemia-reperfusion induced by occlusion of the superior mesenteric artery during 60 mins and reperfused for 180 mins. At the time of reperfusion, animals were administered with LP17 (a synthetic TREM-1 inhibitor), a control peptide, or a vehicle (normal saline). Plasma concentrations of tumor necrosis factor-alpha, interleukin-6, and soluble TREM-1 were measured by enzyme-linked immunosorbent assay. Hepatic activation of the transcriptional factor nuclear factor-kappaB was assessed by electrophoretic mobility shift assay. Hepatic oxidant-antioxidant balance was estimated by measurement of lipid peroxidation and catalase activity. Ileal mucosal permeability was estimated by fluorescein dextran-4 clearance and bacterial translocation by mesenteric lymph nodes culture.
MEASUREMENTS AND MAIN RESULTS: Ischemia-reperfusion was associated with cardiovascular collapse, lactic acidosis, and systemic and hepatic inflammatory response that were partly prevented by LP17 administration. Liver lipid peroxidation and catalase depletion were attenuated by LP17. Ischemia-reperfusion induced a marked increase in ileal mucosal permeability and an associated bacterial translocation that was also prevented by TREM-1 modulation. LP17 delayed mortality.
CONCLUSIONS: The modulation of the TREM-1 pathway by the means of a synthetic peptide may be useful during acute mesenteric ischemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18091551     DOI: 10.1097/01.CCM.0B013E318161FAF3

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  24 in total

1.  A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition.

Authors:  Valerie Cuvier; Ulrike Lorch; Stephan Witte; Aurelie Olivier; Sebastien Gibot; Isabelle Delor; Jean-Jacques Garaud; Marc Derive; Margarita Salcedo-Magguilli
Journal:  Br J Clin Pharmacol       Date:  2018-07-20       Impact factor: 4.335

2.  Triggering receptor expressed on myeloid cells-1 as a new therapeutic target during inflammatory diseases.

Authors:  Marc Derive; Frédéric Massin; Sébastien Gibot
Journal:  Self Nonself       Date:  2010-07-02

Review 3.  Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside.

Authors:  B Levy; S Collin; N Sennoun; N Ducrocq; A Kimmoun; P Asfar; P Perez; F Meziani
Journal:  Intensive Care Med       Date:  2010-09-23       Impact factor: 17.440

4.  Blockade of TREM-1 prevents vitreoretinal neovascularization in mice with oxygen-induced retinopathy.

Authors:  Modesto A Rojas; Zu T Shen; Ruth B Caldwell; Alexander B Sigalov
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-05-03       Impact factor: 5.187

5.  Inhibition of a triggering receptor expressed on myeloid cells-1 (TREM-1) with an extracellular cold-inducible RNA-binding protein (eCIRP)-derived peptide protects mice from intestinal ischemia-reperfusion injury.

Authors:  Naomi-Liza Denning; Monowar Aziz; Mahendar Ochani; Jose M Prince; Ping Wang
Journal:  Surgery       Date:  2020-05-18       Impact factor: 3.982

6.  Inhibition of the Interaction of TREM-1 and eCIRP Attenuates Inflammation and Improves Survival in Hepatic Ischemia/Reperfusion.

Authors:  Timothy Borjas; Asha Jacob; HaoTing Yen; Vihas Patel; Gene F Coppa; Monowar Aziz; Ping Wang
Journal:  Shock       Date:  2022-02-01       Impact factor: 3.454

7.  Etomidate Mitigates Lipopolysaccharide-Induced CD14 and TREM-1 Expression, NF-κB Activation, and Pro-inflammatory Cytokine Production in Rat Macrophages.

Authors:  Ming Liu; Yu Zhang; Jun-Yu Xiong; Yan Wang; Shen Lv
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

8.  A novel ligand-independent peptide inhibitor of TREM-1 suppresses tumor growth in human lung cancer xenografts and prolongs survival of mice with lipopolysaccharide-induced septic shock.

Authors:  Alexander B Sigalov
Journal:  Int Immunopharmacol       Date:  2014-05-14       Impact factor: 4.932

Review 9.  Current trends in inflammatory and immunomodulatory mediators in sepsis.

Authors:  Monowar Aziz; Asha Jacob; Weng-Lang Yang; Akihisa Matsuda; Ping Wang
Journal:  J Leukoc Biol       Date:  2012-11-07       Impact factor: 4.962

10.  TREM-1 Promotes Pancreatitis-Associated Intestinal Barrier Dysfunction.

Authors:  Shengchun Dang; Yao Shen; Kai Yin; Jianxin Zhang
Journal:  Gastroenterol Res Pract       Date:  2012-05-07       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.